Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis

 
• By Joseph Haas, Jessica Merrill, Emily Hayes, and Anju Ghangurde

Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.

DealWatch_1200x675

More from Deals

More from Business